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Lymphoplasmacytic lymphoma/immunocytoma (LPL) is a rare form of B-cell NHL, arising from plasma cells, characterized by high serum levels of monoclonal immunoglobulins with cryoglobulinemia and usually bone marrow infiltration of small lymphocytes showing evidence of plasmacytoid or plasma-cell differentiation. 2 The term Waldenströ m macroglobulinemia (WM) refers specifically to LPL patients with an exceeding and widely variable serum level of monoclonal IgM. 2 The etiology of LPL is largely unknown. The two major acknowledged risk factors are a pre-existing IgM monoclonal gammopathy of uncertain significance (MGUS) and a history of hepatitis C virus infection. 2 The only case-control study published included 65 WM patients, and reported an excess risk for a higher educational level, but no significant differences between other socio-demographic indicators, tobacco or alcohol consumption, and history of medical conditions. 3 A heritable component of WM has been suggested by the reported occurrence in multiplecase families, but a reliable estimate of the proportion of all LPL occurring in the family setting remains undefined. 4 Using the 2004 update of the Swedish Family-Cancer Database, we assessed the familial risk of LPL in relatives with different types of neoplasms.
The Swedish Family-Cancer Database includes all persons born in Sweden after 1931, totaling over 10.5 million individuals, organized in 3.6 million nuclear families. 5 Tumor data were retrieved from the Swedish Cancer Registry from years 1958 to 2002. From 1993 onward, histopathology has been recorded according to the SNOMED (http//www.snomed.org). The Swedish Cancer Registry is based on compulsory reports of individual cases provided separately by clinicians and pathologists/cytologists and is considered to have almost 100% completeness. All NHL diagnoses are based on histological verification. The diagnosis of LPL was based on bone biopsy specimens showing evidence of small plasmacytoid/plasma-cell lymphocytes. WM was confirmed by LPL diagnosis with IgM monoclonal protein of any concentration. We assessed familial risk of LPL for offspring whose parents or siblings were affected by Hodgkin lymphoma, NHL, multiple myeloma, chronic lymphocytic leukemia and other common neoplasms. Between 1993 and 2002, 213 LPL patients (142 immunocytomas, 71 WMs) were diagnosed. Follow-up was started on the date of birth, immigration, or 1 January 1993, whichever occurred last. Follow-up ended on the date of the first primary neoplasm diagnosis, death, emigration or the closing date of the study, 31 December 2002, whichever occurred first. Standardized incidence ratios (SIRs) were used to estimate familial relative risks computed as the ratio of the number of observed cases to the number of expected cases. Expected numbers were based on incidence rates standardized for sex, age, socioeconomic status, residential area and parity. Confidence intervals (95% CIs) were calculated under the assumption of a Poisson distribution.
The Database contained 4544 cases of NHL, 213 (4.7%) of whom had LPL (142 men, 71 women; mean diagnostic age 56, range, 21-70). Table 1 shows familial risks of LPL for offspring with a parent or a sibling affected with most common lymphoproliferative malignancies. In all, 10 LPL cases had a parental history of NHL, and 3 LPL cases had a sibling affected with NHL. The histopathologic information was available for eight of the 13 familial cases, which were diagnosed after 1993. The SIRs for individuals with a parental history of NHL were significantly increased for NHL (SIR ¼ 4.0) and chronic lymphocytic leukemia (SIR ¼ 4.1). A similar, but not significant, pattern of risk was found for siblings of affected cases. The SIRs were 15.4 for a parental history of centroblastic NHL and 43.4 for LPL. The risk of LPL for siblings of cases affected with B-cell NHL was 16.6. No substantial difference was observed in terms of familial risk between LPL and WM. Table 2 gives the familial risks of LPL according to sex and age at diagnosis for individuals with a parental history of NHL. The familial risk of LPL was higher in males (SIR ¼ 4.8), for age at diagnosis p51 years (SIR ¼ 5.5) and for a parental age at diagnosis p60 years (SIR ¼ 7.8). We also explored the familial association of LPL with other common malignancies. A parental history of gastric cancer increased the familial risk of LPL (number of observed cases 11, expected 5.2; SIR ¼ 2.1, 95% CI, 1.1-3.1). No association emerged with other common neoplasms. The present study provides original data showing a strong familial clustering of LPL with NHL and chronic lymphocytic lymphoma. The quantification of the familial aggregation of LPL is a novel finding that could be revealed only by applying SNOMED codes. The association was stronger for a concordant LPL malignancy. The magnitude of the familial risks was similar in parents and siblings of LPL affected cases. In previous studies, familial cases of LPL have been reported to differ from sporadic cases in age and gender distribution, being diagnosed at least a decade earlier and more likely to be males. 4 We found no substantial difference in the mean age at diagnosis between familial and nonfamilial cases, and a sex distribution with a male/female sex ratio of approximately 2.5. The gender difference in the pattern of the familial risk of LPL that we observed is not readily explained and may reflect small sample size or as yet unrecognized endocrine or genetic factors. The familial risks in strata of age suggest that familial cases are more likely to be diagnosed at an early onset. The association found with gastric cancer is an unexpected finding and has never been reported, but it is particularly intriguing. Helicobacter pylori (H. pylori) infection has long been associated with gastric cancer. 6 A similar association has been consistently reported H. pylori and B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the stomach, that share histopathologic features with LPL, but to our knowledge the association between LPL with H. pylori has never been reported. 7, 8 The familial clustering of LPL in offspring with a parent affected with gastric cancer suggests that H. pylori may be important not only in the development of gastric cancer and MALT lymphoma, but perhaps also in LPL. The strength of this study was the availability of reliable histopathologic data from an unselected population with registered based family relations, excluding any type of recall bias. Even though Waldenströ m was a Swede and macroglobulinemias have been well known in the Country, their diagnostic criteria may have changed over the decades, as they have for all lymphomas. Re-examination of the pathological specimens available from our Database has led to the adjustment of the original Hodgkin's disease diagnosis to NHL in some 10% of cases in broad agreement with results from other populationbased studies. 2 These data suggest that the proportion of diagnostic misclassification for NHL is not likely to substantially affect risk estimates from cancer registry-based studies; any random misclassification would bias the results towards null, no effect, opposite to the present findings. Moreover, in our study the histopathologic-specific diagnoses of the parents and the offspring were made between 1993 and 2002. In such a short period of time, we assumed diagnostics to be relatively consistent, and the histopathologic associations found not likely to be biased by different diagnostic criteria between the parents and the offspring. Among the limitations, there is the low number of familial cases due to the rarity of the disease and to the relative young age of the cohort, and our inability to distinguish between heritable genetic and environmental factors as causes of tumor familial aggregation. If environmental factors can be excluded, the high familial risk observed suggest underlying genetic susceptibility. The sum does not add to the total of non-Hodgkin lymphomas because the parental histopathologic information was available only for 8 of the 13 familial cases. LPL ¼ lymphoplasmacytic lymphoma; nos ¼ not otherwise specified; CLL ¼ chronic lymphocytic lymphoma.
Table 2
Familial risk of lymphoplasmacytic lymphoma for a parental history of non-Hodgkin lymphoma, according to sex and age at diagnosis Note that the maximal age in the offspring population is 70 years.
